Pain Therapeutics (PTIE) Earning Somewhat Favorable Media Coverage, Report Finds

Media coverage about Pain Therapeutics (NASDAQ:PTIE) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.3098524834412 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Pain Therapeutics (NASDAQ PTIE) traded down $0.01 on Tuesday, hitting $3.78. The stock had a trading volume of 127,500 shares, compared to its average volume of 182,252. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter. research analysts expect that Pain Therapeutics will post -2.2 earnings per share for the current year.

A number of brokerages have recently commented on PTIE. Zacks Investment Research cut shares of Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Gabelli cut shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 17th.

COPYRIGHT VIOLATION WARNING: This report was originally published by Week Herald and is the property of of Week Herald. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply